Lioudaki Eirini, Androulakis Emmanouil S, Whyte Martin, Stylianou Konstantinos G, Daphnis Eugenios K, Ganotakis Emmanouil S
Renal Unit, Epsom and St. Helier University Hospitals NHS Trust, Wrythe Ln, Carshalton, London, SM5 1AA, UK.
Department of Nephrology, University Hospital of Heraklion, Iraklio, Greece.
Cardiovasc Drugs Ther. 2017 Apr;31(2):215-225. doi: 10.1007/s10557-017-6724-3.
Type 2 diabetes mellitus (T2DM) has growing prevalence worldwide and major clinical implications, chiefly cardiovascular (CV) and renal disease burden. Sodium-glucose co-transporter (SGLT)-2 inhibitors are a new drug class in the management of T2DM with a mechanism of action independent of insulin. In addition to their hypoglycaemic effect, SGLT-2 inhibitors appear to have haemodynamic and nephroprotective effects. Studies have consistently showed a modest but significant blood pressure (BP) reduction. Metabolic benefits are also attributed to SGLT-2 inhibitors with a modest but consistent body weight decrease recorded along with improvements in lipid profile and uric acid levels. Remarkable findings of significant cardioprotective effects came from the recent EMPA-REG study with a particular focus on heart failure. In the kidney, SGLT-2 inhibitors reduce hyperfiltration, a precipitant of diabetic nephropathy.
2型糖尿病（T2DM）在全球范围内的患病率不断上升，并具有重大的临床影响，主要是心血管（CV）和肾脏疾病负担。钠-葡萄糖协同转运蛋白（SGLT）-2抑制剂是治疗T2DM的一类新药，其作用机制独立于胰岛素。除了降血糖作用外，SGLT-2抑制剂似乎还具有血流动力学和肾脏保护作用。研究一直表明，其能使血压适度但显著降低。SGLT-2抑制剂还具有代谢益处，体重适度但持续下降，同时血脂谱和尿酸水平有所改善。近期的EMPA-REG研究得出了显著心脏保护作用的惊人发现，该研究特别关注心力衰竭。在肾脏方面，SGLT-2抑制剂可减少高滤过，而高滤过是糖尿病肾病的一个诱因。
